Business Description
Lineage Cell Therapeutics Inc
NAICS : 541713
SIC : 2836
ISIN : US09066L1052
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 12.02 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.12 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -2.36 | |||||
Beneish M-Score | 0.39 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 118.3 | |||||
3-Year EBITDA Growth Rate | 5.2 | |||||
3-Year EPS without NRI Growth Rate | 6.2 | |||||
3-Year FCF Growth Rate | -8.6 | |||||
3-Year Book Growth Rate | -16.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.11 | |||||
9-Day RSI | 47.62 | |||||
14-Day RSI | 47.53 | |||||
6-1 Month Momentum % | 23.07 | |||||
12-1 Month Momentum % | -5.37 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.14 | |||||
Quick Ratio | 2.14 | |||||
Cash Ratio | 1.98 | |||||
Days Sales Outstanding | 17.3 | |||||
Days Payable | 1312.15 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.6 | |||||
Shareholder Yield % | -3.17 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 92.5 | |||||
Operating Margin % | -276.5 | |||||
Net Margin % | -240.2 | |||||
FCF Margin % | -326.89 | |||||
ROE % | -30.87 | |||||
ROA % | -19.33 | |||||
ROIC % | -29.75 | |||||
ROC (Joel Greenblatt) % | -472.22 | |||||
ROCE % | -26.33 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 22.29 | |||||
PB Ratio | 3.2 | |||||
Price-to-Tangible-Book | 29.11 | |||||
EV-to-EBIT | -7.6 | |||||
EV-to-Forward-EBIT | -8.93 | |||||
EV-to-EBITDA | -7.81 | |||||
EV-to-Forward-EBITDA | -8.93 | |||||
EV-to-Revenue | 21.02 | |||||
EV-to-Forward-Revenue | 17.73 | |||||
EV-to-FCF | -6.44 | |||||
Price-to-Median-PS-Value | 0.21 | |||||
Earnings Yield (Greenblatt) % | -13.15 | |||||
FCF Yield % | -13.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Lineage Cell Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₪) | 33.267 | ||
EPS (TTM) (₪) | -0.447 | ||
Beta | 0 | ||
Volatility % | 51.61 | ||
14-Day RSI | 47.53 | ||
14-Day ATR (₪) | 0.320088 | ||
20-Day SMA (₪) | 4.50375 | ||
12-1 Month Momentum % | -5.37 | ||
52-Week Range (₪) | 3.38 - 6.69 | ||
Shares Outstanding (Mil) | 188.8 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Lineage Cell Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Lineage Cell Therapeutics Inc Stock Events
Event | Date | Price(₪) | ||
---|---|---|---|---|
No Event Data |
Lineage Cell Therapeutics Inc Frequently Asked Questions
What is Lineage Cell Therapeutics Inc(XTAE:LCTX)'s stock price today?
When is next earnings date of Lineage Cell Therapeutics Inc(XTAE:LCTX)?
Does Lineage Cell Therapeutics Inc(XTAE:LCTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |